Moscow, Russia

Grigorii Tzeitline



 

Average Co-Inventor Count = 4.9

ph-index = 4

Forward Citations = 61(Granted Patents)


Company Filing History:


Years Active: 2001-2009

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Grigorii Tzeitline: Innovator in Bisphosphonate Conjugates

Introduction

Grigorii Tzeitline is a notable inventor based in Moscow, Russia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of bisphosphonate conjugates. With a total of 4 patents to his name, Tzeitline's work focuses on innovative treatments for bone-related diseases.

Latest Patents

Tzeitline's latest patents include groundbreaking inventions such as "Bisphosphonate conjugates and methods of making and using the same." This invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising these conjugates, and methods for using them in the treatment of bone cancer, bone-related diseases, and diseases of the soft tissues surrounding bones. Another significant patent is "Biphosphonate conjugates and methods of making and using the same," which is directed towards specific bisphosphonate compounds that are useful in treating soft tissues surrounding bone and conditions like osteoporosis.

Career Highlights

Throughout his career, Tzeitline has worked with various organizations, including Mbc Research, Inc. and Mbc Pharma, Inc. His expertise in the pharmaceutical field has allowed him to develop innovative solutions that address critical health issues.

Collaborations

Tzeitline has collaborated with notable professionals in his field, including Nelly Padioukova and Sergey Mikhailov. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Grigorii Tzeitline is a distinguished inventor whose work in bisphosphonate conjugates has the potential to significantly impact the treatment of bone-related diseases. His innovative patents and collaborations highlight his commitment to advancing pharmaceutical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…